We describe a method for generating regulatory, memory and naïve T cells from a single human blood donor. Polarized Tregs can be then compared to other subsets in a variety of genetic and functional applications with genetic homogeneity, including a suppression assay also detailed here.
The development and maintenance of immunosuppressive CD4+ regulatory T cells (Tregs) contribute to the peripheral tolerance needed to remain in immunologic homeostasis with the vast amount of self and commensal antigens in and on the human body. Perturbations in the balance between Tregs and inflammatory conventional T cells can result in immunopathology or cancer. Although therapeutic injection of Tregs has been shown to be efficacious in murine models of colitis1 , type I diabetes2 , rheumatoid arthritis and graft versus host disease,4 several fundamental differences in human versus mouse Treg biology5 has thus far precluded clinical use. The lack of sufficient number, purity, stability and homing specificity of therapeutic Tregs necessitated a dynamic platform of human Treg development on which to optimize conditions for their ex vivo expansion6.
Here we describe a method for the differentiation of induced Tregs (iTregs) from a single human peripheral blood donor which can be broken down into four stages: isolation of peripheral blood mononuclear cells, magnetic selection of CD4+ T cells, in vitro cell culture and fluorescence activated cell sorting (FACS) of T cell subsets. Since the Treg signature transcription factor forkhead box P3 (FoxP3) is an activation-induced transcription factor in humans7 and no other unique marker exists, a combinatorial panel of markers must be used to identify T cells with suppressor activity. After six days in culture, cells in our system can be demarcated into naïve T cells, memory T cells or iTregs based on their relative expression of CD25 and CD45RA. As memory and naïve T cells have different reported polarization requirements and plasticities8 , pre-sorting of the initial T cell population into CD45RA+ and CD45RO+ subsets can be used to examine these discrepancies. Consistent with others, our CD25HiCD45RA– iTregs express high levels of FoxP39 , GITR and CTLA-411 and low levels of CD12712 . Following FACS of each population, resultant cells can be used in a suppressor assay which evaluates the relative ability to retard the proliferation of carboxyfluorescein succinimidyl ester (CFSE)-labeled autologous T cells.
1. Isolation of Human Peripheral Blood Mononuclear Cells (PBMCs) from Buffy Coat
This procedure can be scaled down for smaller volumes of blood. Dilution of whole blood samples is 1:1 in PBS.
2. Magnetic Negative Selection of Total CD4+ T Cells, CD4+ CD45RA+ naïve T Cells or CD4+ CD45RO+ Memory T Cells from PBMCs using EasySep Enrichment Kits (Stem Cell Technologies)
Steps to follow for 1 x 108 to 4.25 x 108 PBMCs.
3. Cell Culture Conditions to Induce Regulatory T Cells
4. Fluorescence-Activated Cell Sorting (FACS) of Three Populations of T Cells
5. Suppression Assay
6. Representative Results
Example of flow cytometric pseudocolor dot plots over a five-day time-course monitoring iTreg differentiation based on the relative co-expression of CD25 with FoxP3, CTLA-4 and CD45RA can be seen in Figure 2. The histogram in Figure 3 shows a successful suppression assay in which sorted iTregs (CD25HiCD45RA– CD127-/LOW cells) are the only subset from a five-day culture that has acquired regulatory/suppressor ability. Figure 4 shows the induction of Tregs from a naïve T cell pool (top panels) and a memory T cell pool (bottom panels), after five-day culture in standard iTreg medium. CFSE staining of initial cells demonstrate that either naïve (top right panel) or memory T cells (bottom right panel) differentiate to iTregs (highest FoxP3-expressing cells) only after several rounds of cell division.
Figure 1. Schematic of experimental procedure. PBMCs are separated out of human peripheral blood via gradient centrifugation before magnetic negative selection of CD4+CD25– T cells. After five to six days in culture, cells undergo FACS and are co-incubated with heterologous CFSE labeled target cells to measure suppressor activity.
Figure 2. Purified human primary CD4+CD25– T cells are cultured in iTreg medium. An aliquot of cells is collected just after isolation (day 0) and at days 1, 3 and 5 of cell culture to monitor the progress of CD45RA, FoxP3, CTLA-4 and CD25 markers. The iTreg profile corresponds to CD45RA–, FoxP3Hi, CTLA-4Hi and CD25Hi (highlighted in the in-graph window).
Figure 3. Purified CD4+ CFSE labeled cells (1 x 105/well) are cultured with Treg suppression inspector beads in the presence of sorted naïve, memory or iTreg cells (3 x 104/ well). After five days, cells are harvested and the CFSE profile of the stained cells is analyzed by flow cytometry. The presence of iTreg cells completely abolishes the proliferation of CD4+ T cells. Numbers are indicative of percentage of CFSE-labeled cells that have undergone division.
Figure 4. Purified human primary naïve (CD4+CD25–CD45RA+) and memory (CD4+CD25–CD45RO+) T cells are stained with CFSE and cultured in iTreg medium. After five days, cells are phenotyped and the cell division rates estimated. As indicated in Figure 2, the iTreg subset differentiated from both subsets corresponds to CD45RA–CD25Hi FoxP3Hi and CTLA-4Hi (latter two not shown). Comparative CFSE staining profiles identify iTregs (here as the highest expressing FoxP3 T cells) as the most proliferative cells during the five-day culture.
While Treg transfer holds enormous therapeutic promise in combating autoimmunity graft rejection and other immune or inflammatory-mediated disorders, methods for their efficient generation and stable maintenance have not yet been developed. As only 1-5% of circulating human T cells are Tregs, their controlled expansion and differentiation overcomes this paucity as a major deterrent of implementation of Tregs into the clinic. On the other hand, as we learned from the TGN1412 trial13 , it is scientifically and ethically necessary to profoundly understand the molecular events that orchestrate human T cell fate decisions before implementing any therapeutic regimen. With this method of iTreg differentiation, the resulting populations of naïve, memory, effector T cells and iTregs facilitate gene expression or functional comparisons between populations of cells which derive from a single human peripheral blood donor. In our hands, sorted cells have been compared in microarray and qRT-PCR analyses to measure genetic changes, in western blots to examine key signaling events, or in patch clamping to functionally measure ion channel usage14 .
Our system provides the additional benefit of the ability to manipulate key aspects of the differentiation process around a central framework and readout. Thus, one can pre-sort PBMCs to alter the input population of cells or include small molecule inhibitors and ligands to the culture medium. One can also transfect cells to overexpress or knock down a protein of interest or introduce a reporter construct. As an additional benefit, we can alter the conditions of culture to maximize the percentage of iTregs generated. Overall, this human primary T cell culture delineates a very robust experimental platform with a physiological relevance much greater than those created in murine systems. Importantly, it may also sustain a direct therapeutic value. Indeed, as most current Treg-based therapeutic approaches involve in vitro or ex vivo development or manipulation of cells, our system can be seen as an important conduit on the road towards inclusion of Treg cell therapy in the standard of care. Future expansions on this system will tailor Tregs to become activated upon encounter with specific in vivo inflammatory antigens rather than the polyclonal activation described.
The authors have nothing to disclose.
The authors wish to thank Jennifer Strange and Greg Bauman for their assistance with Flow Cytometry analysis and sorting. This work was supported by the NIH Grant Number 2P20 RR020171 from the NCRR and by University of Kentucky startup funds to F.M.; G.I.E. acknowledges the support of the Presidential Graduate Fellowship and the Kentucky Opportunity Fellowship.
Name of the reagent | Company | Catalogue Number | コメント |
Lymphoprep | Axis-Shield | 1114547 | Keep at room temperature |
Refrigerated Bench-Top Centrifuge | Eppendorf | 5810R | |
Bright-Line Hemocytometer | Hausser Scientific | 3110 | |
EasySep Human CD4+ T Cell Enrichment Kit | Stem Cell Technologies | 19052 | |
EasySep Human Memory CD4+ T Cell Enrichment Kit | Stem Cell Technologies | 19157 | |
EasySep Human Naïve CD4+ T Cell Enrichment Kit | Stem Cell Technologies | 19155 | |
The Big Easy EasySep Magnet | Stem Cell Technologies | 18001 | Silver |
5 mL Round Bottom Polystyrene Tubes | BD Falcon | 352008 | |
15 mL Polypropylene Centrifuge Tubes | VWR | 89004-368 | |
14 mL Polypropylene Round-Bottom Tubes | BD Falcon | 352059 | |
50 mL Polypropylene Centrifuge Tubes | VWR | 89004-364 | |
Human anti-CD3 Antibody | Bio X Cell | BE0001-2 | Clone: OKT3 |
24 Well Cell Polystyrene Culture Plate | BD Falcon | 353047 | |
96 Well Round Bottom Tissue Culture Plate | Grenier Bio-One | 650180 | |
RPMI 1640 with Glutamax-I and HEPES Buffer | Gibco | 72400 | |
Fetal Bovine Serum (FBS) | Gibco | 16000 | |
β-Mercaptoethanol | Sigma | M7522 | |
Recombinant Human TGF-β1 | eBioscience | 14-8348-62 | |
Recombinant Human IL-2 | eBioscience | 14-8029-63 | |
Bovine Serum Albumin (BSA) | MP Biomedicals Inc. | 810531 | |
0.5 M EDTA | Amresco | E177 | |
Mouse Anti-Human CD25-PE | Miltenyi Biotec | 130-091-024 | Clone: 4E3 |
Mouse Anti-Human CD45RA-PE-Cy5 | eBioscience | 15-0458-42 | Clone: HI100 |
Mouse Anti-Human CD127-APC | Miltenyi Biotec | 130-094-890 | Clone: MB15-18C9 |
DNase II | MP Biomedicals Inc. | 190370 | |
MoFlo Flow Cytometer | Beckman Coulter | ||
FlowJo Software | Tree Star, Inc. | ||
Cell Quest Pro Software | BD Biosciences | ||
Newborn Calf Serum | Gibco | 16010 | |
L-glutamine | Gibco | 25030 | |
AIM-V | Gibco | 0870112 | |
CellTrace CFSE Cell Proliferation Kit | Invitrogen | C34554 | |
Treg Suppression Inspector Beads | Miltenyi Biotec | 130-092-909 | |
Penicillin-Streptomycin | Gibco | 15140 | |
40 μM Nylon Cell Strainer | BD Falcon | 352340 |